Perspective Therapeutics shares fell 29% to $3.19 after presenting Phase 1/2a trial data for VMT-alpha-NET. Analysts split on outlook despite favorable safety profile and $174M cash position through late 2026.
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
Sanofi's experimental atopic dermatitis drug, amlitelimab, met trial goals but disappointed investors by falling short of blockbuster Dupixent's efficacy, sending shares plunging and raising concerns about the company's pipeline post-2031 patent expiry.
